DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20211125

Study of depot medroxyprogesterone acetate as an extended postpartum contraceptive at SCB medical college and hospital, Cuttack

Sagarika Samal, Lucy Das

Abstract


Background: Increase in contraceptive use during the postpartum period substantially reduces the rate of maternal and infant mortality by preventing unplanned and unwanted pregnancies. Injectable Medroxy Progesterone acetate (DMPA) is one long acting reversible safe and effective method for postpartm contraception. Aims and Objectives to study the acceptance, efficacy, side effects and compliance of DMPA as an extended postpartum contraceptive at SCB Medical College, Cuttack.

Methods: The study includes 76 women between 6weeks to 1year postpartum who had chosen DMPA as contraceptive after counseling regarding the basket of choices. DMPA injection was given within 7 days of menstruation if it has returned or at any time after being confirmed that woman is not pregnant with a back up for first 7days. Subsequent injections were given at three monthly intervals and followed up for one year after the first injection for pregnancy rate, side-effects, discontinuation and patient satisfaction.

Results: Maximum females were from the combined age groups 25-29 (39.47%) and 20-24 years (35.52%). 46.1% women belong to lower middle socioeconomic group. The most common menstrual problem was amenorrhea in 47.36% followed by scanty bleeding in 22.36%. 25% discontinued after 1st dose of injection, which is the maximum. The commonest reason for discontinuation observed was menstrual problems (37.93%) followed by use of other methods of contraception (17.24%). Out of 76, 23 women were not satisfied (30.26%), main reason of dissatisfaction being menstrual problems. Failure rate was nil.

Conclusions: The study concludes that DMPA is a very effective, safe, and long acting contraceptive with no effect on lactation. Proper counseling can improve the acceptance and compliance.


Keywords


Acceptability, Compliance, Contraception, DMPA, Side effects

Full Text:

PDF

References


2030 Agenda - Sustainable Development - the United Nations Available from https://sustainabledevelopment.un.org › post2015 › transformingourworld.

Family planning – MoHFW Available from https://mohfw.gov.in Chapter 915.

Family planning: the unfinished agenda*John Cleland, Stan Bernstein, Alex Ezeh, Anibal Faundes, Anna Glasier, Jolene Innis The Lancet 368(9549):1810-27 · December 2006 DOI: 10.1016/S0140-6736(06)69480-4 · Source: PubMed

National Family Health Survey (NFHS-4)rchiips.org › nfhs › India

Injectable contraceptive (dmpa) - National Health Mission MP)https://www.nhmmp.gov.in › Guideline2017 › Injectable_Manual

Glasier A "Contraception". In DeGroot LJ, Jameson JL (eds.). Endocrinology (5th ed.). Philadelphia: Elsevier Saunders. 2006;2993.

Loose DS, Stancel GM "Estrogens and Progestins". In Brunton LL, Lazo JS, Parker KL (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. 2006; 1541-71.

Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices". American J Obstetr Gynecol. 1999;181(5.1):1263-9.

Trussell J. Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart FH, Nelson AL, Cates Jr W, Guest F, Kowal D. Contraceptive Technology, 17th ed (revised). New York, NY, Ardent Media, 2004: 773-845.

Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety". Contraception. 2003;68(2):75-87.

Machin D, Farley TM, Busca B, Campbell MJ, d'Arcangues C. Assessing changes in vaginal bleeding patterns in contracepting women. Contraception. 1988;38(2):165-79.

Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74:90-9.

Sirisha PSNRS. Efficacy of Depot medroxy Progesterone Acetate As A Contraceptive. 2017; 4(12).

Affandi B. Long-acting progestogens. Best Pract Res Clin Obstet Gynaecol. 2002;16(2):169-79.

Aktun H, Moroy P, Cakmak P, Yalcin HR, Leyla M, Danisman N. Depo-Provera: Use of A Long-acting Progestin Injectable in Turkish Women Contraception. 2005;72(1):24-7.

Rai L, Prabaka P, Nair S. Injectable Depot Medroxy progesterone-A safe and effective contraception for an Indian Setting Health and Population-Perspectives and Issues. 2007;30(1):12-23.

Ruminjo JK, Sekadde-Kigondu CB, Karanja JG, Rivera R, Nasution M, Nutley T. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception. 2005;72(2):138-45.

Wellings K, Zhihong Z, Krentel A, Barrett G, Glasier A. Attitudes towards long-acting reversible methods of contraception in general practice in the UK. Contraception. 2007;76(3):208-14.

Aladag N, Filiz M, Topsever P, Apaydin P, Gorpelioglu S. Satisfaction among women: differences between current users of barrier (male condom) and non-barrier methods. Eur J Contracept Reprod Health Care. 2006;11(2):81-8.

Prabhakaran S. Sweet A Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability. Contraception. 2012;85:453-7.